Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1564)	6/20/2002 12:32:36 PM
From: tuck	Read Replies (1) \| Respond to of 1728

Hi, Nigel, The CodeLink system was launched last August. Just for the hell of it, I tried entering "CodeLink" in PubMed. The one hit was from MOT itself hyping it: >>Nucleic Acids Res 2002 Apr 1;30(7):e30 Related Articles, Books, LinkOut An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. Ramakrishnan R, Dorris D, Lublinsky A, Nguyen A, Domanus M, Prokhorova A, Gieser L, Touma E, Lockner R, Tata M, Zhu X, Patterson M, Shippy R, Sendera TJ, Mazumder A. Motorola Life Sciences, 4088 Commercial Avenue, Northbrook, IL 60062, USA. ramesh.ramakrishnan@motorola.com DNA microarrays enable users to obtain information on differences in transcript abundance on a massively parallel scale. Recently, however, data analyses have revealed potential pitfalls related to image acquisition, variability and misclassifications in replicate measurements, cross-hybridization and sensitivity limitations. We have generated a series of analytical tools to address the manufacturing, detection and data analysis components of a microarray experiment. Together, we have used these tools to optimize performance in an expression profiling study. We demonstrate three significant advantages of the Motorola CodeLink platform: sensitivity of one copy per cell, coefficients of variation of 10% in the hybridization signals across slides and across target preparations, and specificity in distinguishing highly homologous sequences. Slides where oligonucleotide probes are spotted in 6-fold redundancy were used to demonstrate the effect of replication on data quality. Lastly, the differential expression ratios obtained with the CodeLink expression platform were validated against those obtained with quantitative reverse transcription-PCR assays for 54 genes.<< Tellingly, A similar exercise substituting "GeneChip" yielded four pages of hits (and I know there's more than that with different key words). To me, this implies Motorola is getting no traction. Why, I don't know. Cheers, Tuck